121 related articles for article (PubMed ID: 27181081)
1. Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study.
Elsayed M; Kobayashi D; Kubota T; Matsunaga N; Murata R; Yoshizawa Y; Watanabe N; Matsuura T; Tsurudome Y; Ogino T; Ohdo S; Shimazoe T
Biol Pharm Bull; 2016 Aug; 39(8):1238-46. PubMed ID: 27181081
[TBL] [Abstract][Full Text] [Related]
2. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L
Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells.
Fujita M; Tohi M; Sawada K; Yamamoto Y; Nakamura T; Yagami T; Yamamori M; Okamura N
Oncol Rep; 2012 May; 27(5):1371-6. PubMed ID: 22322451
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A
Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
6. Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins.
Yu R; Longo J; van Leeuwen JE; Mullen PJ; Ba-Alawi W; Haibe-Kains B; Penn LZ
Cancer Res; 2018 Mar; 78(5):1347-1357. PubMed ID: 29229608
[TBL] [Abstract][Full Text] [Related]
7. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways.
Kotamraju S; Williams CL; Kalyanaraman B
Cancer Res; 2007 Aug; 67(15):7386-94. PubMed ID: 17671209
[TBL] [Abstract][Full Text] [Related]
8. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
Knight LA; Kurbacher CM; Glaysher S; Fernando A; Reichelt R; Dexel S; Reinhold U; Cree IA
BMC Cancer; 2009 Jan; 9():38. PubMed ID: 19175937
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis.
Nagashima T; Okazaki H; Yudoh K; Matsuno H; Minota S
Arthritis Rheum; 2006 Feb; 54(2):579-86. PubMed ID: 16447234
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells.
Bocci G; Fioravanti A; Orlandi P; Bernardini N; Collecchi P; Del Tacca M; Danesi R
Br J Cancer; 2005 Aug; 93(3):319-30. PubMed ID: 16052215
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.
Vintonenko N; Jais JP; Kassis N; Abdelkarim M; Perret GY; Lecouvey M; Crepin M; Di Benedetto M
Mol Pharmacol; 2012 Sep; 82(3):521-8. PubMed ID: 22723339
[TBL] [Abstract][Full Text] [Related]
14. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
15. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.
Honda Y; Takahashi S; Zhang Y; Ono A; Murakami E; Shi N; Kawaoka T; Miki D; Tsuge M; Hiraga N; Abe H; Ochi H; Imamura M; Aikata H; Chayama K
J Gastroenterol Hepatol; 2015 Mar; 30(3):619-27. PubMed ID: 25167891
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
17. Isoprenoids influence expression of Ras and Ras-related proteins.
Holstein SA; Wohlford-Lenane CL; Hohl RJ
Biochemistry; 2002 Nov; 41(46):13698-704. PubMed ID: 12427032
[TBL] [Abstract][Full Text] [Related]
18. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Sonnemann J; Bumbul B; Beck JF
Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts.
Carlin CM; Peacock AJ; Welsh DJ
Am J Respir Cell Mol Biol; 2007 Oct; 37(4):447-56. PubMed ID: 17556673
[TBL] [Abstract][Full Text] [Related]
20. Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms.
Kanugula AK; Gollavilli PN; Vasamsetti SB; Karnewar S; Gopoju R; Ummanni R; Kotamraju S
FEBS J; 2014 Aug; 281(16):3719-38. PubMed ID: 24964743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
